Valion Bio annual stock-based compensation
2021
2022
2023
2024
2025
Valion Bio Stock-Based Compensation Growth & History (VBIO)
Valion Bio's stock-based compensation was $564,000 for fiscal 2025.
View full Valion Bio company overviewValion Bio annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $564,000 | $335,000 | +146.29% |
| 2024 | 2024-12-31 | $229,000 | −$42,000 | −15.50% |
| 2023 | 2023-12-31 | $271,000 | −$127,000 | −31.91% |
| 2022 | 2022-12-31 | $398,000 | $341,000 | +598.25% |
| 2021 | 2021-12-31 | $57,000 | — | — |
Valion Bio quarterly stock-based compensation
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $133,000 | −$43,000 | −24.43% |
| Q1 2026 | 2026-03-31 | $208,000 | $108,000 | +108.00% |
| Q4 2025 | 2025-12-31 | $149,000 | $86,000 | +136.51% |
| Q3 2025 | 2025-09-30 | $139,000 | $81,000 | +139.66% |
| Q2 2025 | 2025-06-30 | $176,000 | $122,000 | +225.93% |
| Q1 2025 | 2025-03-31 | $100,000 | $46,000 | +85.19% |
| Q4 2024 | 2024-12-31 | $63,000 | $5,000 | +8.62% |
| Q3 2024 | 2024-09-30 | $58,000 | $10,000 | +20.83% |
| Q2 2024 | 2024-06-30 | $54,000 | −$27,000 | −33.33% |
| Q1 2024 | 2024-03-31 | $54,000 | −$30,000 | −35.71% |
| Q4 2023 | 2023-12-31 | $58,000 | −$54,000 | −48.21% |
| Q3 2023 | 2023-09-30 | $48,000 | −$65,000 | −57.52% |
| Q2 2023 | 2023-06-30 | $81,000 | −$31,000 | −27.68% |
| Q1 2023 | 2023-03-31 | $84,000 | $23,000 | +37.70% |
| Q4 2022 | 2022-12-31 | $112,000 | $96,000 | +600.00% |
| Q3 2022 | 2022-09-30 | $113,000 | $90,000 | +391.30% |
| Q2 2022 | 2022-06-30 | $112,000 | $104,000 | +1300.00% |
| Q1 2022 | 2022-03-31 | $61,000 | $51,000 | +510.00% |
| Q4 2021 | 2021-12-31 | $16,000 | — | — |
| Q3 2021 | 2021-09-30 | $23,000 | — | — |
| Q2 2021 | 2021-06-30 | $8,000 | — | — |
| Q1 2021 | 2021-03-31 | $10,000 | — | — |
Valion Bio stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Valion Bio's stock-based compensation increased from $57,000 to $564,000, a change of $507,000. The latest reported quarter, Q2 2026, shows $133,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Valion Bio source filings ↗